{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:48Z","timestamp":1792601688936,"version":"4.5.0"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1R18HS025345"],"award-info":[{"award-number":["1R18HS025345"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019945","name":"University of New Mexico Clinical and Translational Science Center","doi-asserted-by":"crossref","award":["CTSC, UL1TR001449"],"award-info":[{"award-number":["CTSC, UL1TR001449"]}],"id":[{"id":"10.13039\/100019945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lack of access to buprenorphine to treat Opioid Use Disorder is profound in rural areas where over half of small and remote rural counties have no buprenorphine prescriber. To increase prescribing, an online, Medication of Opioid Use Disorder (MOUD) Extensions for Community Healthcare Outcomes (ECHO) was developed that addressed known barriers to the startup and expansion of treatment. The objective of the present study was to determine the relationship between participating in MOUD ECHO sessions and prescribing of buprenorphine for OUD in rural primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using non-random, rolling-recruitment from Feb 2018 to October of 2021, all rural primary care clinics in New Mexico were contacted via phone call and fax to recruit providers (Physicians, Nurse Practitioners, and Physician Assistants) who had no or limited buprenorphine experience to enroll in this study. Participation in the MOUD ECHO was tracked across the 12\u2009week series. Start-up and expansion of buprenorphine treatment was measured every 3\u2009months for up to 2\u2009years using 5 implementation benchmarks spanning training completion, obtaining licensure, prescribing and adding patients. Using a dose-response intention to treat type analysis, associations between number of sessions and benchmark achievement were analyzed using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eighty providers were enrolled, mostly female (66%) white (82%), non-Hispanic (82%), and mostly nurse practitioners (51%) or MDs (38%). Achievement of prescribing benchmarks at 6\u2009months was significantly increased by attendance at MOUD ECHO sessions including obtaining training and licensure Odds Ratio (OR\u2009=\u20091.24; P\u2009=\u2009.001); starting to prescribe (OR\u2009=\u20091.31; P\u2009=\u2009.004), and adding patients (OR\u2009=\u20091.14; P\u2009=\u2009.025).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study provides compelling evidence that MOUD ECHO participation may significantly increase the number of providers implementing this treatment and adding patients onto their panels. The dose-response approach helps address current gaps in ECHO research that call for more rigorous examination of the ECHO model\u2019s impact on provider practice improvements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08897077231198971","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:45:51Z","timestamp":1698644751000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care"],"prefix":"10.1177","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4594-9899","authenticated-orcid":false,"given":"Julie G.","family":"Salvador","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin B.","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal R.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Jacobsohn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Lindsey","sequence":"additional","affiliation":[{"name":"Addictions and Substance Abuse Programs, University of New Mexico Hospital, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana S.","family":"Alkhafaji","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Rishel Brakey","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Sussman","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"bibr1-08897077231198971","unstructured":"Centers for Disease Control and Prevention (CDC). Understanding the Epidemic; 2023. Accessed October 12, 2023 at https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html"},{"key":"bibr2-08897077231198971","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4"},{"key":"bibr3-08897077231198971","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"Mancher M","year":"2019"},{"key":"bibr4-08897077231198971","unstructured":"Substance Abuse and Mental Health Services Administration. MAT medications, counseling, and related conditions; 2022. Accessed August 1, 2022. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/medications-counseling-related-conditions\/buprenorphine"},{"key":"bibr5-08897077231198971","unstructured":"Substance Abuse and Mental Health Services Administration. Removal of DATA waiver (X-Waiver) requirement; 2023. Accessed May 15, 2023. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement"},{"key":"bibr6-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00637-z"},{"key":"bibr7-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub2."},{"key":"bibr8-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"bibr9-08897077231198971","unstructured":"Providers Clinical Support Systems (PCSS). Overview of medications for opioid use disorder (MOUD); 2022. Accessed August 1, 2022. https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/"},{"key":"bibr10-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000918"},{"key":"bibr11-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12569"},{"key":"bibr12-08897077231198971","unstructured":"California Health Foundation. Recovery within reach: medication assisted treatment of opioid addiction comes to primary care. 2016. Accessed August 12, 2021. https:\/\/www.chcf.org\/wp-content\/uploads\/2017\/12\/PDF-RecoveryReachMAT.pdf"},{"key":"bibr13-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1016\/j.evalprogplan.2011.02.004"},{"key":"bibr14-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009370"},{"key":"bibr15-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000001328"},{"key":"bibr16-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05291-1"},{"key":"bibr17-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00215-z"},{"key":"bibr18-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201600471"},{"key":"bibr19-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.08.014"},{"key":"bibr20-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21085"},{"key":"bibr21-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900142"},{"key":"bibr22-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1806184"},{"key":"bibr23-08897077231198971","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2021.06.210111"},{"key":"bibr24-08897077231198971","doi-asserted-by":"publisher","DOI":"10.2307\/2531248"},{"key":"bibr25-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1177\/1094428104268542"},{"key":"bibr26-08897077231198971","doi-asserted-by":"publisher","DOI":"10.3102\/10769986211017480"},{"key":"bibr27-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387"},{"key":"bibr28-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"bibr29-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5941"},{"key":"bibr30-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000933"},{"key":"bibr31-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12419"},{"key":"bibr32-08897077231198971","unstructured":"The Pew Charitable Trusts. Why aren\u2019t more people with opioid use disorder getting buprenorphine? 2 Experts discuss ways to expand access to this effective drug. 2019. Accessed September 20, 2022. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/articles\/2019\/07\/31\/why-arent-more-people-with-opioid-use-disorder-getting-buprenorphine."},{"key":"bibr33-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2421"},{"key":"bibr34-08897077231198971","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000765"},{"key":"bibr35-08897077231198971","author":"Stringfellow E","year":"2021","journal-title":"Health Aff"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08897077231198971","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08897077231198971","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08897077231198971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:40:24Z","timestamp":1777668024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08897077231198971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/08897077231198971"],"URL":"https:\/\/doi.org\/10.1177\/08897077231198971","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}